Pulmonology Advisor (9/16, May) reports a review study suggests that “long-acting naltrexone is a promising approach for opioid use disorder (OUD), but its use has clinical implications in critically ill patients who are receiving sedation and analgesia.” The review study was published in Annals of the American Thoracic Society.
Related Links:
— “Managing Sedation, Analgesia in Critically Ill Patients Receiving Naltrexone “Brandon May, Pulmonology Advisor, September 16, 2020